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Abstract
Background: We have previously demonstrated that tumour islet infiltration by macrophages is associated with 
extended survival (ES) in NSCLC. We therefore hypothesised that patients with improved survival would have high 
tumour islet expression of chemokine receptors known to be associated with favourable prognosis in cancer. This 
study investigated chemokine receptor expression in the tumour islets and stroma in NSCLC.
Methods: We used immunohistochemistry to identify cells expressing CXCR1, CXCR2, CXCR3, CXCR4, CXCR5 and CCR1 
in the tumour islets and stroma in 20 patients with surgically resected NSCLC. Correlations were made with 
macrophage and mast cell expression.
Results: There was increased expression of CXCR2, CXCR3, and CCR1 in the tumour islets of ES compared with poor 
survival (PS) patients (p = 0.007, 0.01, and 0.002, respectively). There was an association between 5 year survival and 
tumour islet CXCR2, CXCR3 and CCR1 density (p = 0.02, 0.003 and <0.001, respectively) as well as stromal CXCR3 density 
(p = 0.003). There was a positive correlation between macrophage density and CXCR3 expression (rs = 0.520, p = 0.02) 
and between mast cell density and CXCR3 expression (rs = 0.499, p = 0.03) in the tumour islets.
Conclusion: Above median expression of CXCR2, CXCR3 and CCR1 in the tumour islets is associated with increased 
survival in NSCLC, and expression of CXCR3 correlates with increased macrophage and mast cell infiltration in the 
tumour islets.
Background
We have demonstrated previously that the tissue micro-
localisation of immune cells in surgically resected
NSCLC is a key determinant of patient survival [1,2]. In
particular, when macrophages are located within tumour
epithelial islets, a striking improvement in patient sur-
vival is evident. This supports the view that these islet-
associated macrophages contribute to cytotoxic mecha-
nisms which limit tumour dissemination. It is not known
why some patients have high levels of potentially cyto-
toxic cells in their tumour islets and others do not, but
the expression of macrophage-recruiting chemokines
within the tumour islets by either tumour cells them-
selves or infiltrating immune cells is likely to be a key
mechanism. Therefore an improved understanding of
chemoattractant pathways that are active may lead to the
development of novel chemotherapeutic agents.
Chemokines are cytokines that have chemotactic prop-
erties influencing cell migration [3]. Chemokines them-
s e l v e s  a r e  r e l e a s e d  i n  r e s p o n s e  t o  c e l l  a c t i v a t i o n  b y
diverse cytokines and pathologic stimuli [3]. The
chemokine superfamily consists of over 40 ligands and
approximately 20 receptors [3]. They can be classified
into four groups: -CXC-, -CC-, -C- and -CX3C - accord-
ing to amino acid position at the N terminal. Several
chemokines have been shown to be present in cancer tis-
sue including CCL2, CCL3, CCL4, CCL5, CCL8, CCL17,
CCL18, CCL20, CCL21, CCL22, CCL27, CCL28, CXCL1,
CXCL2, CXCL8, CXCL9, CXCL10, CXCL12, and
CXCL13 [4-6]. An important ligand/receptor pair is
CXCL12 and CXCR4 which may be involved in the regu-
lation of metastasis in NSCLC [7]. CCL5 activates CCR1,
-3 and -5, and CCL5 expression by tumour cells in
patients with stage I lung adenocarcinoma has been asso-
ciated with improved survival [8]. CXCL8 (interleukin-8)
has two chemokine receptors, CXCR1 and CXCR2 [9].
CXCL8 is a mediator of angiogenesis in lung cancer [10]
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and correlates with angiogenesis, tumour progression
and poor survival in NSCLC [11,12]. Zhu found that cell
proliferation was significantly reduced by anti-CXCR1
antibody but not by anti-CXCR2 antibody and concluded
that the mitogenic function of CXCL8 in lung cancer is
mediated mainly by CXCR1 receptor [9]. However, it has
also been demonstrated in a murine model that depletion
of CXCR2 inhibits tumour growth and angiogenesis in
lung cancer [13]. With respect to immune cell infiltration
in cancer, CXCR3, along with IFN-γ, may play an impor-
tant role with respect to NK cell infiltration [14].
The precise localisation of chemokine receptor expres-
sion in NSCLC with respect to tumour islets or stroma
has not been examined. Given that we have demonstrated
previously that the tissue microlocalisation of mac-
rophages and mast cells in NSCLC is intimately related
with outcome, [1,2], we hypothesised that this principle
would also apply to the expression of chemokine recep-
tors. If true, we would expect that patients with improved
survival would have high tumour islet expression of
chemokine receptors known to be associated with
favourable prognosis in cancer such as CXCR3 and
CCR1.
Methods
Study Population
The study was approved by the Leicestershire Research
Ethics Committee. The tissue specimens evaluated were
from 20 patients with NSCLC who had undergone resec-
tion with curative intent at the University Hospitals of
Leicester National Health Service Trust (Leicester, United
Kingdom). These patients had resections during two
periods - one dating from 1991 to 1994 and the second
from January to December 1999. This cohort of patients
has been described previously [1]. Of the 20 patients
studied, 14 were men and average age at surgery was 72.3
years (standard deviation, 6.53; range, 60.2 to 82.4 years).
Full clinicopathologic information was gathered before
and after surgery, including patient characteristics, treat-
ment, combined clinical and surgical staging results (pre-
operative staging by computed tomography scan,
selective mediastinoscopy, and systematic lymph node
sampling at operation), histologic subtype, tumour grade,
and survival data. Patients were divided into two groups,
extended survival (ES) (mean ± SEM 90.8 ± 11.8 months)
and poor survival (PS) (mean ± SEM 7.9 ± 0.8 months).
Patient characteristics are shown in Table 1.
Immunohistology
Specimens studied were formalin fixed and paraffin
embedded. Only blocks containing the advancing edge of
the primary tumour were evaluated. Tissue sections of 4
μm thickness were cut onto glass slides and then de-
waxed in xylene and rehydrated through graded alcohols.
Antigen retrieval was carried out using Trilogy Antigen
Retrieval solution (Cell Marque, Hot Springs, United
States of America) in a pressure cooker (heated to
117.5°C for 1 min and then cooled to 100°C for 30 sec-
onds). Mouse antihuman antibodies were used (all R & D
Systems Europe, Abingdon, United Kingdom) as follows:
CXCR1 (clone 42705), CXCR2 (clone 48311), CXCR3
(clone 49801), CXCR4 (clone 44716), CXCR5 (clone
51505) and CCR1 (clone 53504). Immunostaining was
performed and the chemokine receptors were developed
with peroxidase and 3,3'-diaminobenzidine tetrahydro-
chloride (brown reaction product). Sections were then
counterstained with haematoxylin and mounted in an
aqueous mounting medium (BDH Chemicals Ltd, Poole,
United Kingdom). Appropriate isotype controls were per-
formed where the primary antibodies were replaced by
irrelevant mouse mAb of the same isotype and at the
same concentration as the specific primary mAb.
Analysis and Validation of Immunostaining
Analysis was performed blind with respect to the clinical
outcome. The ten most representative high-power fields
(x400) per slide were manually selected using an Olym-
pus BX50 microscope (Olympus, Southall, United King-
dom). The respective areas of stroma and of tumour-cell
islets were then measured at ×400 magnification using
Analysis imaging software (Soft Imaging System GmbH).
The number of nucleated macrophages and cells with
positive staining for the phenotype marker in each area
were then counted manually and expressed as cells/mm2
of stroma or tumour islets. Analysis was repeated for 5
patients to assess repeatability and validity.
Statistical Analysis
Statistical analyses were carried out using the GraphPad
Prism software package (v. 4.02; GraphPad Prism Soft-
ware Inc, San Diego, CA). For categoric analysis, the
median value was used as a cut point to dichotomise the
series. The χ2  test was used to test for relationships
between categoric variables, and the Mann-Whitney
nonparametric test was used to compare categoric with
continuous variables. Kaplan-Meier survival curves were
used to look for correlations with survival and were com-
pared with the use of the log-rank statistic. For the above
comparisons, p < 0.05 was considered statistically signifi-
cant.
Results
Patient Characteristics
Patent characteristics are shown in Table 1. Of the 20
patients studied, 15 had died at the time of analysis. Four-
teen tumours were squamous, 3 adenocarcinoma, 2 large
cell, and 1 other. Fourteen were stage I and 6 stage II. NoOhri et al. BMC Cancer 2010, 10:172
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patients had additional postoperative chemotherapy and
2 had additional radiotherapy for later palliation.
Validation of Analysis
Clear and distinguishable staining was evident for the
chemokine receptors studied (Fig 1). Appropriate isotype
controls were negative. In order to assess the validity of
the method, area measurements and cell counts were
repeated and intraclass correlation coefficients calcu-
lated. Good correlations were found for both: 0.997 (95%
CI, 0.996 to 0.998, p < 0.001) and 0.995 (95% CI, 0.993 to
0.997, p < 0.001). This method of analysis has also been
validated by our group previously [1,2].
Cellular Distribution
The majority of chemokine receptor immunostaining in
the tumour islets was present in inflammatory cells and
r a r e l y  s e e n  o n  t u m o u r  e p i t h e l i a l  c e l l s.  S i m i l a r l y  i n  t h e
stroma, immunostaining was also seen in inflammatory
cells with no expression evident on vessels. There was
significantly increased expression of CXCR2, CXCR3,
and CCR1 in the tumour islets of ES compared with PS
Table 1: Patient characteristics
Characteristic Extended Survival Poor Survival
No. of patients 10 10
Age - years 72.0 ± 2.5 72.6 ± 1.6
Male sex - no. (%) 8 (80) 6 (60)
Year of surgery - no. (%)
1992 1 (10) 0 (0)
1994 0 (0) 1 (10)
1999 9 (90) 9 (90)
Tumour stage - no. (%)
1 7 (70) 7 (70)
2 3 (30) 3 (30)
Histology - no. (%)
Squamous 8 (80) 6 (60)
Adenocarcinoma 2 (20) 1 (10)
Large cell 0 (0) 1 (10)
Other 0 (0) 2 (20)
Tumour Grade - no. (%)
Moderate 4 (40) 0 (0)
Poor 6 (60) 10 (100)
Adjuvant Chemotherapy (%) 0 (0) 0 (0)
Radiotherapy (%) 1 (10) 1 (10)
Palliative Radiotherapy (%) 1 (10) 1 (10)
Survival - months 90.8 ± 11.8 7.9 ± 0.8
Plus-minus values are means ± SEMOhri et al. BMC Cancer 2010, 10:172
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patients [median 6.5 versus 2.6, (p = 0.007), 12.7 versus
3.2, (p = 0.01), and 24.3 versus 2.4 cells/mm2, (p = 0.002),
respectively]. There were no significant differences for
CXCR1, CXCR4, or CXCR5 in either the tumour islets or
stroma (Figs 2A and 2B). There was significantly
increased expression of CXCR2, CXCR3 and CXCR4 in
the stroma of ES compared with PS patients (8.9 versus
1.6, (p = 0.04), 51.4 versus 5.9, (p < 0.001), 24.9 versus 3.1,
(p = 0.004) (Figs 2C and 2D).
Kaplan-Meier Survival Analysis
For further analysis, the data were divided into two
groups above and below the median cell count values.
Kaplan-Meier survival curves were plotted to investigate
further the association of cell densities with survival. The
logrank statistic was used to compare survival rates.
There was a positive association between survival and
tumour islet CXCR2 (p = 0.02), CXCR3 (p = 0.003) and
CCR1 (p < 0.001) density, but no significant associations
between survival and tumor islet CXCR1, CXCR4 and
CXCR5 density (Fig 3A-F). After dichotomisation at the
median cell density for cells expressing each marker , 5-
year survival was 50.3% above the median compared with
19.8% below the median for CXCR2, 60.2% versus 9.9%
for CXCR3 and 59.8% versus 9.9% for CCR1. There was a
positive association between survival and stromal
CXCR3 (p = 0.003) density, but no significant associa-
tions between survival and stromal CXCR1, CXCR2,
CXCR4, CXCR5 and CCR1 density (Fig 4A-F).
Correlation with macrophage and mast cell counts
Chemokine receptor expressing cell counts were corre-
lated against islet and stromal macrophage counts which
had been generated previously [1]. It was noted that there
were positive correlations for CXCR3 (rs = 0.520, p =
0.02) and CCR1 (rs = 0.432, p = 0.06) in the islets (Fig 5A
and 5B). With respect to stromal counts there were nega-
tive correlations for CXCR2 (rs  = -0.455, p = 0.04),
CXCR3 (rs = -0.844, p < 0.001) and CXCR4 (rs = -0.606, p
= 0.005)(Fig 5C-E).
Chemokine receptor expressing cell counts were corre-
lated against islet and stromal mast cell counts which had
been generated previously [1]. There was a positive corre-
lation for CXCR3 (rs = 0.499, p = 0.03) in the islets (Fig
5F).
Figure 1 Immunohistology demonstrating positive chemokines receptor expression (brown) for CXCR1 (A), CXCR2 (B), CXCR3 (C), CXCR4 
(D), CXCR5 (E) and CCR1 (F). Magnification ×400.
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Discussion & Conclusions
The purpose of this study was to investigate the expres-
sion of chemokine receptors and their microlocalisation
in surgically resected NSCLC. The results demonstrate
that patients with extended survival have significantly
increased expression of CXCR2, CXCR3 and CCR1 in
their tumour islets compared to patients with poor sur-
vival, and significantly increased expression of CXCR2,
CXCR3 and CXCR4 in their tumour stroma. In addition,
we observed that patients with above median expression
of CXCR2, CXCR3 and CCR1 in their tumour islets and
patients with above median expression of CXCR3 in their
stroma had significantly improved 5-year survival. Inter-
estingly, when chemokine receptor expression was com-
pared with macrophage density in the tumour islets (Fig
5), it was noted that there was a positive correlation with
increasing islet macrophage count and expression of
CXCR3 and CCR1 and also, between islet mast cell num-
bers and CXCR3.
We have demonstrated previously the importance of
cellular microlocalisation in terms of potential sites for
immune cytotoxicity against NSCLC tumours [1,2]. In
particular, NSCLC tumour islets are the likely site of host
cytotoxic responses against tumour development and
progression. Not only does increasing macrophage infil-
tration of NSCLC tumour islets correlate strongly with
survival, but these macrophages are predominantly of the
M1 cytotoxic phenotype [2]. Our current results suggest
Figure 2 Chemokine receptor densities in the tumour islets for extended survival (ES) patients (A) and poor survival (PS) patients (B) and 
in the stroma for ES patients (C) and PS patients (D).
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Figure 3 Kaplan-Meier five year survival curve for chemokines receptor densities in the tumour islets for CXCR1(A), CXCR2 (B), CXCR3 (C), 
CXCR4 (D), CXCR5 (E) and CCR1 (F).
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Figure 4 Kaplan-Meier five year survival curve for chemokines receptor densities in the tumour stroma for CXCR1(A), CXCR2 (B), CXCR3 (C), 
CXCR4 (D), CXCR5 (E) and CCR1 (F).
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Figure 5 Correlations between chemokine receptor and macrophage cell counts in the tumour islets for CXCR3 (A) and CCR1 (B), in the tu-
mour stroma for CXCR2 (C), CXCR3 (D), and CXCR4 (E), and between mast cells and CXCR3 (F) in the tumour islets.
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that the chemokine receptor CCR1 which is expressed by
macrophages, may be involved in the chemotactic path-
way which recruits M1 macrophages into the tumour
islets. Of particular relevance to this, a CCR1 ligand
CCL5, is over-expressed in NSCLC tumours character-
i z e d  b y  T  l y m p h o c y t e  i n f i l t r a t i o n  [ 8 ] .  O f  f u r t h e r  r e l e -
vance, one of the ligands for CCR1 is CCL3 which is
thought to stimulate the production and release of TNFα,
a cytokine that is expressed and which has cytotoxic
potential in the tumour islets [2].
CXCR3 has not been described on macrophages, but is
expressed on cytotoxic NK cells [14], human lung mast
cells [15] and T lymphocytes [16]. These cell types are
associated with improved survival in NSCLC [1,17,18],
and are likely to interact with macrophages in mediating
tumour killing. CXCR3 expression was markedly
increased in both the tumour islets and stroma in NSCLC
patients with extended survival compared to those with
poor survival. Tumours enriched for cells expressing
CXCR3 are likely to be producing excess quantities of one
or all of the CXCR3 ligands, CXCL9, -10 and -11.
CXCL10 has been shown to be expressed by tumour epi-
thelial cells in squamous NSCLC [19]. CXCR3 agonists
protect against tumour dissemination in mouse models
[19-21], observations supported by the improved out-
come associated with increased CXCR3 expression in
this study. In mouse models, CXCR3 ligands are thought
to work predominantly through inhibition of angiogene-
sis, but our findings of CXCR3 expression on numerous
inflammatory cells, suggests an important role in the host
anti-tumour immune response. The CXCR3 ligands can
be produced by a number of inflammatory and structural
cells, and are typically thought of as markers of a Th1
immunological response as they are induced predomi-
nantly by IFNγ and TNFα [22]. Overall, the increased
expression of CXCR3 on inflammatory cells within the
NSCLC tumour stroma and islets in patients with
extended survival, supports the view that cytotoxic cell-
mediated immunity contributes to protection of the host
against NSCLC progression, and suggests that augment-
ing this arm of the immunological response may be bene-
ficial clinically.
Examining the expression and cellular provenance of
the ligands for CXCR3 and CCR1 will be important in
future studies of NSCLC. CCR1 ligands can also be pro-
duced by a variety of immune and structural cells, and
CCL5 is produced by NSCLC tumour epithelial cells [8].
It is attractive to speculate therefore that the key factor
determining the nature, intensity and microlocalisation
of the immune response in NSCLC is the pattern and
intensity of chemokine production by the tumour itself.
Our finding of distinct chemokine receptor patterns in
the tumour and stroma which associate with survival
supports this view.
The chemokine receptor CXCR4 is implicated in the
regulation of cancer growth, metastasis, relapse and
response to treatment. In patients with NSCLC, CXCR4
expression has been found on circulating cytokeratin+
cells, with increased expression correlating with
improved survival [23]. Our results suggest that increased
expression of CXCR4 in the NSCLC stroma relates to
improved survival. From our previous investigations
[1,2], however, the tumour islets appears to be the critical
micro-compartment for host immune responses against
N S C L C .  F u r t h e r  w o r k  w i l l  t h e r e f o r e  b e  r e q u i r e d  t o
understand the biological role of stromal CXCR4 expres-
sion.
The chemokine receptor CXCR2 exerts multiple func-
tions depending on the cell type it is expressed on. In
NSCLC it is generally considered to promote tumorigen-
esis and metastasis through the induction of angiogenesis
[9,13]. However, it is also implicated in the senescence of
pre-neoplastic cells and may inhibit neoplastic transfor-
mation [24]. In our NSCLC tissue samples, CXCR2 in the
tumour islets was not seen on tumour epithelial cells but
was present on inflammatory cells. Interestingly, its
expression was increased in the tumour islets of patients
with extended survival compared to those with poor sur-
vival. This is compatible with the suggestion that loss of
CXCR2 on tumour epithelial cells promotes neoplastic
transformation in NSCLC [24], but also suggests that
CXCR2 may serve to limit tumour growth through its
expression on inflammatory cells recruited to the tumour.
Thus CXCR2 may have dual roles in NSCLC, promoting
tumour progression through the induction of angiogene-
sis in the stroma, but limiting tumour growth through the
recruitment of inflammatory cells to the tumour islets.
Targeting CXCR2 in NSCLC may therefore prove to have
unpredictable effects depending on the relative balance
between these two opposing activities.
In summary, above median expression of the
chemokine receptors CXCR2, CXCR3 and CCR1 in the
tumour islets is associated with increased 5-year survival.
Increased expression of CXCR3 and CCR1 correlates
with increased macrophage expression in the tumour
islets and therefore these receptors may be involved in
the pathway that attracts cytotoxic M1 macrophages,
mast cell, B cells, T cells and NK cells into the tumour
islets. Therefore, if a therapeutic agent could increase the
production of the ligands for CXCR3 and CCR1 by the
tumour epithelial cell, this might lead to an improved
immune response to NSCLC and thus better survival.
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